Trial · NCT00665561
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C AIDS -Defining Opportunistic Infections | Maraviroc Exposed | 22.28 | 95% Confidence Interval 18.57 to 26.73 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C AIDS -Defining Opportunistic Infections | Maraviroc Unexposed | 41.77 | 95% Confidence Interval 36.09 to 48.34 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Viral Encephalitis | Maraviroc Exposed | 0.38 | 95% Confidence Interval 0.10 to 1.54 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Viral Encephalitis | Maraviroc Unexposed | 0.46 | 95% Confidence Interval 0.12 to 1.86 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies) | Maraviroc Exposed | All Malignancies | 12.87 | 95% Confidence Interval 10.13 to 16.35 | events per 1000 participant-years |
| Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies) | Maraviroc Unexposed | All Malignancies | 13.69 | 95% Confidence Interval 10.61 to 17.67 | events per 1000 participant-years |
| Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies) | Maraviroc Exposed | AIDS defining Malignancies | 2.31 | 95% Confidence Interval 1.31 to 4.06 | events per 1000 participant-years |
| Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies) | Maraviroc Unexposed | AIDS defining Malignancies | 3.71 | 95% Confidence Interval 2.27 to 6.06 | events per 1000 participant-years |
| Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies) | Maraviroc Exposed | Non-AIDS defining Malignancies | 10.56 | 95% Confidence Interval 8.11 to 13.76 | events per 1000 participant-years |
| Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies) | Maraviroc Unexposed | Non-AIDS defining Malignancies | 9.98 | 95% Confidence Interval 7.40 to 13.45 | events per 1000 participant-years |
| Density Rate Per 1000 Participant-Years for Incidence of Liver Failure | Maraviroc Exposed | 2.50 | 95% Confidence Interval 1.45 to 4.30 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Liver Failure | Maraviroc Unexposed | 2.55 | 95% Confidence Interval 1.41 to 4.61 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' | Maraviroc Exposed | 4.80 | 95% Confidence Interval 3.24 to 7.11 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' | Maraviroc Unexposed | 5.34 | 95% Confidence Interval 3.55 to 8.03 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data' | Maraviroc Exposed | 8.26 | 95% Confidence Interval 6.13 to 11.14 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data' | Maraviroc Unexposed | 7.43 | 95% Confidence Interval 5.25 to 10.50 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Rhabdomyolysis | Maraviroc Exposed | 0.77 | 95% Confidence Interval 0.29 to 2.05 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Rhabdomyolysis | Maraviroc Unexposed | 0.70 | 95% Confidence Interval 0.22 to 2.16 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Death From Liver-Related Cause | Maraviroc Exposed | 0.77 | 95% Confidence Interval 0.29 to 2.05 | events per 1000 participant-years | |
| Density Rate Per 1000 Participant-Years for Incidence of Death From Liver-Related Cause | Maraviroc Unexposed | 1.16 | 95% Confidence Interval 0.48 to 2.79 | events per 1000 participant-years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00665561/results